Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

NAPLEX 2022 > Infectious Diseases - PART 2 > Flashcards

Infectious Diseases - PART 2 Flashcards

1
Q

AMINOGLYCOSIDE AGENTS

A

GENTAMICIN
TOBRAMYCIN
AMIKACIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

AMINOGLYCOSIDE TOXICITIES

A

NEPHROTOXICITY
OTOTOXICITY
NEUROMUSCULAR BLOCKADE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

AMINOGLYCOSIDE COVERAGE

A

GN (INCLUDING PSEUDOMONAS)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

AMINOGLYCOSIDES ARE COMMONLY USED IN COMBINATION WITH WHICH AGENTS AND WHY?

A

BETA LACTAMS OR VANCOMYCIN

FOR SYNERGY AND TO COVER GP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

AMINOGLYCOSIDE DOSING: UNDERWEIGHT PATIENT

A

USE TOTAL BODY WEIGHT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

AMINOGLYCOSIDE DOSING: OBESE PATIENT

A

ADJUSTED BODY WEIGHT

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

AMINOGLYCOSIDE DOSING: GENTAMICIN AND TOBRAMYCIN TRADITIONAL DOSING

A

1-2.5 MG/KG/DOSE Q8H

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

AMINOGLYCOSIDE DOSING: GENTAMICIN AND TOBRAMYCIN EXTENDED INTERVAL DOSING

A

4-7 MG/KG/DAY Q24H

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

AMINOGLYCOSIDE MONITORING: DRUG LEVEL FOR TRADITIONAL DOSING

A

NEED TROUGH LEVEL RIGHT BEFORE 4TH DOSE AND PEAK 30 MIN AFTER 4TH DOSE

GOAL TROUGH <2
GOAL PEAK 5-10

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

AMINOGLYCOSIDE MONITORING: DRUG LEVEL FOR EXTENDED DOSING

A

RANDOM LEVEL TO DETERMINE DOSING FREQUENCY

NOMOGRAM BASED ON DRUG LEVEL AND TIME BETWEEN START AND RANDOM DRAW

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

QUINOLONE AGENTS

A

CIRPOFLOXACIN
LEVOFLOXACIN
MOXIFLOXACIN
GEMIFLOXACIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

QUINOLONE COVERAGE

A

GN AND GP
ATYPICALS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

RESPIRATORY QUINOLONES

A

LEVOFLOXACIN
MOXIFLOXACIN
GEMIFLOXACIN

HAVE ENHANCED COVERAGE TO S.PNEUMO AND ATYPICAL

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

WHICH QUINOLONES HAVE ENHANCED GN ACTIVITY (INCLUDING TO PSEUDOMONAS)

A

CIPROFLOXACIN
LEVOFLOXACIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

WHICH QUINOLONE CAN NOT BE USED FOR UTIS?

A

MOXIFLOXACIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

WHICH FLUOROQUINOLONE HAS ENHANCED GP AND ANAEROBIC COVERAGE

A

MOXIFLOXACIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

WHICH FLUOROQUINOLONE HAS MRSA COVERAGE?

A

DELAFLOXACIN

OTHER QUINOLONES ARE AVOIDED DUE TO RESISTANCE

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

WHICH FLUOROQUINOLONE DOES NOT REQUIRE RENAL DOSE ADJUSTMENT?

A

MOXIFLOXACIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

WHICH QUINOLONES HAVE IV:PO RATIO OF 1:1?

A

LEVOFLOXACIN AND MOXIFLOXACIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

CAUTION FLUOROQUINOLONE USE IN THESE DISEASE STATES

A

CVD
LOW K OR MG
USE WITH OTHER QT PROLONGING
SEIZURE HISTORY
DIABETES
PSYCHIATRIC CONDITIONS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

WHICH ORAL SUSPENSION SHOULD AVOID ADMINISTRATION WITH NG TUBE OR OTHER FEEDING TUBE?

A

CIPROFLOXACIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

AVOID SYSTEMIC FLUOROQUINOLONES IN THESE POPULATIONS

A
  • PTS WITH SEIZURE HX
  • PEDIATRICS (MUSCULOTOXICITY)
  • PREGNANCY (MUSCULOTOXICITY)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

MACROLIDE AGENTS

A

AZITHROMYCIN
CLARITHROMYCN
ERYTHROMYCIN

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Z-PAK DOSING

A

500 MG DAY 1
250 MG DAY 2-5

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
MACROLIDE COVERAGE
ATYPICALS H FLU
26
MACROLIDE COMMON USE
COMMUNITY ACQUIRED RESPIRATORY INFECTIONS STI (CHLAMYDIA AND GONORRHEA)
27
MACROLIDE WARNING
QT PROLONGATION HEPATOTOXICITY
28
WHICH MACROLID SHOULD BE CAUTIONED IN CAD
CLARITHROMYCIN CAN INCREASE RISK OF DEATH
29
THESE MACROLIDES HAVE HIGH POTENTIAL FOR DDIS BECAUSE THEY DO THIS
CLARITHOMYCIN AND ERYTHROMYCIN STRONG CYP3A4 INHIBITORS
30
TETRACYCLINE AGENTS
DOXYCYCLINE MINOCYCLINE TETRACYCLINE
31
TETRACYCLINE COVERAGE
GPC GN AND ATYPICALS
32
DOXYCYCLINE HAS BROADER INDICATIONS
CAP TICK-BORNE DISEASES STIS (CHLAMYDIA AND GONORRHEA) CA-MRSA SKIN INFECTION VRE UTI
33
WHICH TETRACYCLINE DOES NOT NEED RENAL DOSE ADJUSTMENTS
DOXYCYCLINE
34
TETRACYCLINE WARNINGS
BONE GROWTH AND TEETH DISCOLORATION (CHILDREN < 8 YO, PREGNANCY) PHOTOSENSITIVITY
35
MINOCYCLINE HAS THIS UNIQUE WARNING
DRUG INDUCED LUPUS ERYTHEMATOSUS (DILE)
36
TETRACYCLINE BIOAVAILABILITY (IV:PO RATIO)
GOOD 1:1 FOR DOXY AND MINOCYCLINE
37
SMX/TMP COVERAGE
MRSA UNRELIABLE STREP BROAD GN BACTERIA (SHIGELLA, SALMONELLA, HNPEK) OPPORTUNISTIC PATHOGENS NO PSEUDOMONAS, ENTEROCOCCI, ATYPICAL, OR ANAEROBE COVERAGE
38
WHICH OPPORTUNISTIC PATHOGENS DOES SMX/TMP HAVE COVERAGE?
PNEUMOCYSTUS TOXOPLASMOSIS
39
SMX TMP DOSE IS BASED ON WHICH COMPONENT?
TMP COMPONENT
40
SMX/TMP FORMULATION RATIO
SMX:TMP = 5:1
41
SMX/TMP SS
400 MG SMX 80 MG TMP
42
SMX/TMP DS
800 MG SMX 160 MG TMP
43
SMX/TMP UTI DOSING
1 DS TAB PO BID X 3 DAYS
44
SMX/TMP PCP PROPHYLAXIS DOSING
1 DS OR SS DAILY
45
SMX/TMP WARNINGS
SULFA ALLERGY THROMBOCYTPENIC PURPURA (TTP) G6PD DEFICIENCY (HEMOLYSIS RISK)
46
SMX/TMP SIDE EFFECTS
PHOTOSENSITIVITY ↑ K HEMOLYTIC ANEMIA (POS COOMBS) CRYSTALLURIA
47
SMX/TMP DDI WITH WARFARIN
CAN INCREASE INR SMX/TMP IS A CYP2C9 INHIBITOR
48
VANCOMYCIN COVERAGE
GP BACTERIA (INCLUDING MRSA) C.DIF (PO VANCO) NO VRE
49
VANCOMYCIN IS FIRST LINE IN WHICH INFECTIONS?
MODERATE-SEVERE SYSTEMIC MRSA INFECTION
50
WHEN SHOULD YOU CONSIDER AN ALTERNATIVE AGENT OF VANCOMYCIN?
MRSA MIC ≥ 2
51
VANCOMYCIN IV DOSING FOR SYSTEMIC INFECTION
15 - 20 MG/KG Q8-12H
52
VANCOMYCIN DOSING BASED ON WHAT WEIGHT
TOTAL BODY WEIGHT
53
WHEN TO RENAL DOSE ADJUST VANCOMYCIN AND TO WHAT ADJUSTMENT?
CRCL 20-49 CHANGE TO Q24H
54
VANCOMYCIN C.DIF DOSE
125 MG QID X 10 DAYS
55
VANCOMYCIN WARNINGS
OTOTOXICITY NEPHROTOXICITY
56
FOR SERIOUS MRSA INFECTIONS, WHAT ARE THE THERAPEUTIC DRUG LEVEL GOALS FOR VANCOMYCIN?
AUC/MIC RATIO 400-600 OR GOAL TROUGH 15 - 20 MCG/ML (NORMALLY JUST 10-15 MCG/ML)
57
LIPOGLYCOPEPTIDE AGENTS
TELAVANCIN ORITAVANCIN
58
LIPOGLYCOPEPTIDE APPROVED FOR WHAT INDICATIONS
TELA: SSTI AND HA-VAP ORITA: SSTI
59
TELAVANCIN BOXED WARNINGS
FETAL RISK NEPHROTOXICITY (CRCL ≤ 50)
60
LIPOGLYCOPEPTIDE CONTRAINDICATIONS
CONCURRENT USE OF IV UFH ORITA: DONT USE UFH FOR 120H AFTER ORITA ADMIN CAN INTERFERE WITH aPTT LAB RESULTS
61
LIPOGLYCOPEPTIDE WARNINGS
FALSELY ↑ PT/INR AND OTHER COAGULATION TESTS RED MAN SYNDROME
62
ORITAVANCIN DOSING
ONLY A SINGLE DOSE IS NEEDED DUE TO EXTREMELY LONG HALF-LIFE

NAPLEX 2022 (37 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions